kras mutation and glutathion mutation: from undruggable to druggable in cancer Targeting KRAS Mutant Cancers with
Targeting KRAS Mutant Cancers with a Covalent G12C Specific Inhibitor: Cell What should we know about the 'undruggable' target KRAS? MedChemExpress Rerouting the drug response: Overcoming metabolic adaptation in KRAS mutant cancers Science Signaling The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy Molecular Cancer Springer Nature Link glutathione and pancreatic cancer How survives ferroptosis? Pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations exhibit Promising direction for the treatment of pancreatic cancers driven by KRAS mutation Der Lab
Pay in 4 interest-free payments of $7.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20




